## METHODS AND STANDARDS OF ESTABLISHING PAYMENT RATES - OTHER MEDICAL CARE (Continued)

## 32. 1905(a)(29) Medication-Assisted Treatment (MAT)

MAT is covered under the Medicaid State Plan for all Medicaid beneficiaries who meet the medical necessity criteria for receipt of the service for the period beginning October 1, 2020 and ending September 30, 2025.

- a) Opioid Treatment Programs (OTP) receive per-member, per-month (PMPM) reimbursement for MAT services and provision of methadone. OTPs must provide at least one MAT encounter per month to receive a PMPM rate. Effective 7/1/2023 through 3/31/2024 3/31/2025, the PMPM rate without health home services is \$400.90. Effective 4/1/2024 4/1/2025, the PMPM rate without health home services is \$388.88. Effective 7/1/2023 through 3/31/2025, the PMPM rate without health home services is \$388.88. Effective 7/1/2023 through 3/31/2025, the PMPM rate with health home services is \$572.72. Effective 4/1/2025, the PMPM rate with health home services is \$555.53.
- b) Payment for authorized providers of MAT services other than OTPs is made at the lower of the actual charge for the MAT service or the Medicaid rate on file. For services payable in Medicare's Resource Based Relative Values Scale payment methodology, the DVHA is utilizing the Medicare RBRVS RVUs, the Medicare GPCIs, and State determined conversion factors as specified in Section 26. The RBRVS methodology was updated for dates of service effective as specified in Section 26 of Attachment 4.19-B. All rates are published on the DVHA website. Except as otherwise noted in the plan, State developed fee schedule rates are the same for both governmental and private.
- c) Unbundled prescribed MAT drugs that are delivered by OTPs or are physician administered, other than methadone, are reimbursed according to the Physician Administered Drugs fee schedule at Item 12(a)(9) of Attachment 4.19-B.
- d) Unbundled MAT prescribed drugs and biologicals used to treat opioid use disorder (OUD) that are delivered by authorized providers other than OTPs are reimbursed in the same manner as the Prescribed Drug methodology as listed in Item 12(a) of Attachment 4.19-B.